$1.6494
0.0494[3.09%]
At close: Apr 24
$1.6494
0[0.00%]
PreMarket: 6:40PM EDT
Plus Therapeutics
(NASDAQ:PSTV)Latest News for Plus Therapeutics Stock (NASDAQ:PSTV)
Plus Therapeutics Stock (NASDAQ: PSTV)
Categories: All
Monday, April 22, 2024
- Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of DefenseVandana Singh - 3 days ago
- Plus Therapeutics Says 'Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline'Benzinga Newsdesk - 3 days ago
- Plus Therapeutics Receives $3M Award Recommendation From The U.S. Department Of DefenseBenzinga Newsdesk - 3 days ago
Monday, March 25, 2024
Tuesday, March 05, 2024
Monday, March 04, 2024
Monday, December 18, 2023
Tuesday, December 12, 2023
Monday, November 20, 2023
Thursday, November 09, 2023
Friday, November 03, 2023
Wednesday, November 01, 2023
- Why Plus Therapeutics Stock Popped TodayRyan Gustafson - Nov 1, 2023, 3:38PM
- Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Nov 1, 2023, 1:59PM
- Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving PremarketLisa Levin - Nov 1, 2023, 8:07AM
Tuesday, October 31, 2023
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Oct 31, 2023, 5:31PM
- Plus Therapeutics shares are trading higher after the company reported Q3 financial results and announced a share repurchase program.Benzinga Newsdesk - Oct 31, 2023, 4:24PM
- Plus Therapeutics Announces Share Repurchase Program To Repurchase Up To $500,000 Of Common StockBenzinga Newsdesk - Oct 31, 2023, 4:20PM
- Plus Therapeutics Q3 EPS $(1.00) Vs $(2.85) Last Year, Sales $1.24M Miss $1.29M EstimateBenzinga Newsdesk - Oct 31, 2023, 4:06PM
- Earnings Scheduled For October 31, 2023Benzinga Insights - Oct 31, 2023, 5:44AM
Monday, October 30, 2023
Monday, October 16, 2023
Tuesday, October 10, 2023
Friday, September 29, 2023
Thursday, September 21, 2023
Monday, September 18, 2023
Monday, September 11, 2023
- Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Sep 11, 2023, 1:38PM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Sep 11, 2023, 9:06AM
- Plus Therapeutics Receives $1.9 Million Advance Payment From CPRIT; To Present Data From Its ReSPECT-LM Clinical TrialBenzinga Newsdesk - Sep 11, 2023, 7:06AM
Friday, September 08, 2023
- Plus Therapeutics shares are trading lower after the company announced a licensing agreement with Biocept.Benzinga Newsdesk - Sep 8, 2023, 3:52PM
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Sep 8, 2023, 1:31PM
- Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?Vandana Singh - Sep 8, 2023, 9:18AM
- EXCLUSIVE: Plus Therapeutics Tells Benzinga 'As part of the agreement, Plus obtains a nonexclusive license and option for exclusivity for patients receiving CNS radiotherapy'Benzinga Newsdesk - Sep 8, 2023, 6:30AM
- EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System CancersVandana Singh - Sep 8, 2023, 6:30AM
- EXCLUSIVE: Plus Therapeutics Tells Benzinga Co Enters Into License Agreement For Cerebrospinal Fluid Tumor Cell Enumeration AssayBenzinga Newsdesk - Sep 8, 2023, 6:30AM
Tuesday, September 05, 2023
Tuesday, August 15, 2023
Monday, August 14, 2023
- Plus Therapeutics Q2 EPS $(0.59) Beats $(1.91) Estimate, Sales $1.85M Beat $790.00K EstimateBenzinga Newsdesk - Aug 14, 2023, 4:36PM
- Plus Therapeutics Presents Exciting New Clinical Data At Top Cancer ConferenceJohnny Rice - Aug 14, 2023, 1:34PM
- Earnings Scheduled For August 14, 2023Benzinga Insights - Aug 14, 2023, 6:45AM
- HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price TargetBenzinga Newsdesk - Aug 14, 2023, 6:35AM
Friday, August 11, 2023
- Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Aug 11, 2023, 1:47PM
- Plus Therapeutics Earnings PreviewBenzinga Insights - Aug 11, 2023, 1:02PM
- EXCLUSIVE: Plus Therapeutics Tells Benzinga 'FDA approves continuation to Phase 1 Part B of the ReSPECT-LM clinical trial'Benzinga Newsdesk - Aug 11, 2023, 6:00AM
- EXCLUSIVE: Plus Therapeutics Tells Benzinga 'Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases'Benzinga Newsdesk - Aug 11, 2023, 6:00AM
- EXCLUSIVE: Plus Therapeutics Tells Benzinga Co Reports ReSPECT-LM Phase I Trial Data At The 2023 SNO/ASCO CNS Cancer ConferenceBenzinga Newsdesk - Aug 11, 2023, 6:00AM
- EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain CancerVandana Singh - Aug 11, 2023, 6:00AM